

**Supplementary Table 4. Incidence of treatment-emergent adverse events and adverse drug reaction**

	TEAEs		ADRs	
	N (%)	Event	N (%)	Event
Renal and urinary disorders				
Polyuria	10 (8.55)	11	10 (8.55)	11
Pollakiuria	8 (6.84)	8	8 (6.84)	8
Nocturia	6 (5.13)	7	6 (5.13)	7
Acute kidney injury	1 (0.85)	1	1 (0.85)	1
Micturition urgency	1 (0.85)	1	1 (0.85)	1
Renal pain	1 (0.85)	1	1 (0.85)	1
Ureterolithiasis	1 (0.85)	1	1 (0.85)	1
General disorders				
Thirst	9 (7.69)	11	9 (7.69)	11
Fatigue	2 (1.71)	2	2 (1.71)	2
Nervous system disorders				
Headache	5(4.27)	7	2(1.71)	4
Dizziness	3(2.56)	3	2(1.71)	2
Liver injury				
ALT elevation	3 (2.56)	3	3 (2.56)	3
ALT > 3 ×ULN <sup>a</sup>	1 (0.85)	1	1 (0.85)	1
AST elevation	2 (1.71)	2	2 (1.71)	2
AST > 3 ×ULN <sup>a</sup>	1 (0.85)	1	1 (0.85)	1
Gastrointestinal disorders				
Constipation	3(2.56)	3	2(1.71)	2
Diarrhea	3(2.56)	3	3(2.56)	3

<sup>a</sup>Liver injury was defined as ALT or AST elevation (>3 × ULN) or total bilirubin elevation (>2 × ULN) as safety endpoints. AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.